Trial Profile

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 09 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tucatinib (Primary) ; Trastuzumab emtansine
Indications Advanced breast cancer; Brain metastases; Carcinoma; HER2 positive breast cancer; Male breast cancer
Focus Registrational; Therapeutic Use
Acronyms HER2CLIMB-02
Sponsors Pfizer; Seagen

29 May 2025 Planned End Date changed from 28 Oct 2027 to 10 Mar 2029.
30 Apr 2025 Results evaluating efficacy and safety and pharmacokinetics of tucatinib in combination with T-DM1 versus placebo in combination with T-DM1 presented at the 116th Annual Meeting of the American Association for Cancer Research.
22 Apr 2025 Planned End Date changed from 31 Oct 2027 to 28 Oct 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com